Startseite>>Signaling Pathways>> GPCR/G protein>> Prostaglandin Receptor>>AZ12672857

AZ12672857

Katalog-Nr.GC60611

AZ12672857 ist ein oral aktiver Inhibitor von EphB4 (IC50=1,3 nM) und Src-Kinasen. AZ12672857 zeigt eine gute Hemmung der Proliferation von c-Src-transfizierten 3T3-Zellen (IC50 = 2 nM) sowie eine Autophosphorylierung von EphB4 in transfizierten CHO-K1-Zellen (IC50 = 9 nM).

Products are for research use only. Not for human use. We do not sell to patients.

AZ12672857 Chemische Struktur

Cas No.: 945396-55-4

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
397,00 $
Auf Lager
5mg
371,00 $
Auf Lager
10mg
630,00 $
Auf Lager
25mg
1.251,00 $
Auf Lager
50mg
2.039,00 $
Auf Lager
100mg
3.152,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

AZ12672857 is an orally active inhibitor of EphB4 (IC50=1.3 nM) and Src kinases. AZ12672857 shows good inhibition of proliferation of c-Src transfected 3T3 cells (IC50=2 nM) as well as autophosphorylation of EphB4 in transfected CHO-K1 cells (IC50=9 nM)[1].

AZ12672857 shows only modest inhibition of CYP P450 (IC50=5 μM against 2C9 and 3A4, >10 μM against 1A4, 2D6 and 2C19). AZ12672857 inhibits p-KDR in HUVEC with an IC50 of 240 nM and inhibits p-PDGFR-βin MG63 cell line with an IC50 of 58 nM[1].

[1]. Bardelle C, et al. Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors. Bioorg Med Chem Lett. 2010;20(21):6242-6245.

Bewertungen

Review for AZ12672857

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AZ12672857

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.